Postherpetic neuralgia,PHN
Conditions
Interventions
A: Group A: Patients receiving only botulinum toxin type A injections.:None
Group B: Patients receiving triamcinolone acetonide injection only:None
Group D: Patients receiving combined botulinum toxin type A injection and floating needle therapy:None
Group E: Patients receiving combined triamcinolone acetonide injection and floating needle therapy:None
Group C: Patients receiving floating needle therapy only:None
Sponsors
Yuebei People’s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with postherpetic neuralgia (PHN) between January 2020 and December 2023, with pain persisting for more than 12 months after healing of the herpes zoster rash, and showing inadequate response to conventional medications (e.g., gabapentin, pregabalin). 2.Complete medical records with fully documented treatment plans and follow-up data (including VAS scores at baseline, 7 days post-treatment, and 30 days post-treatment); 3.Age between 18 and 80 years.
Exclusion criteria
Exclusion criteria: 1. Presence of severe organ disease or contraindications to treatment (determined from medical records, surgical notes, or laboratory reports); 2.Participation in other interventional studies concurrently.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analog Scale; | — |
Countries
China
Contacts
Public ContactXiao Bao
Yuebei People’s Hospital
Outcome results
None listed